Recent manuscripts
Archive
Aims and Scope
Editorial Board
Open Access
Indexing
Contact us
Authorship & COI
Publication Ethics
Crossmark
Data Policies
Supporting Diversity
Instructions to authors (PDF)
Manuscript Types
Manuscript Formatting
Professional Editing Service
How to submit
Supplements & Special Issues
Preprints
TID on Twitter
Acute effect of an e-cigarette with and without nicotine on lung function
1,
1,
1,
1,
1,
1,
1
| 1 | Research unit for Tobacco Control, 1st Respiratory Department, University of Athens, Medical School, Sotiria Hospital, Athens, Greece |
CORRESPONDING AUTHOR
Anastasios Palamidas
Research unit for Tobacco Control, 1st Respiratory Department, University of Athens, Medical School, Sotiria Hospital, Athens, 11527, Greece
Research unit for Tobacco Control, 1st Respiratory Department, University of Athens, Medical School, Sotiria Hospital, Athens, 11527, Greece
Publication date: 2014-06-06
Tobacco Induced Diseases 2014;12(Suppl 1):AA34
KEYWORDS
ABSTRACT
Background:
E-cig is an electrical device that vaporizes propylene or polyethylene glycol-based liquid solution into an aerosol mist containing different concentration of nicotine. Our preliminary study showed an increase in Raw, a concomitant decrease in sGaw and an increase in slope of phase III in a limited number of subjects immediately after smoking a single e–cig containing nicotine.
Methods:
We extended our protocol in a larger group of never smokers and in smokers. We implemented the same protocol with a nicotine free e-cig in a group of never smokers. We studied 60 subjects before and after smoking an e-cig containing 11mg nicotine (Group A). Group A: 9 never smokers and 51 smokers (24 had no overt airways disease, 11 asthma, 16 COPD). Another group of 10 never smokers used a nicotine free e-cig (Group B). Lung function assessed pre and post e-cig use including lung volumes, airway resistance (Raw), specific airway conductance (sGaw) and the slope of phase III. The same brand of e-cig used in both groups, with 11 and 0mg of nicotine.
Results:
Group A: a significant increase in Raw was shown in smokers and in never smokers (0.284±0.13-0.308±0.14; p= 0.033, 0.246±0.07-0.292±0.05; p=0.006) with significant decrease in sGaw (1.197±0.50-1.060±0.42; p= 0.009, 1.313±0.22-1.109±0.18; p= 0.043). Increased slope in phase III was shown only in asthmatic patients (p=0.008). Group B: increase in Raw (0.247±0.03-0.333±0.08; p=0.005) and a decrease in sGaw (1.213±0.29-0.944±0.18; p=0.009) noted.
Conclusions:
The present study supports our preliminary results showing increased Raw and a concomitant decrease in sGaw. These changes might be due to the vaporizing liquid but not to the inhaled nicotine per se.
E-cig is an electrical device that vaporizes propylene or polyethylene glycol-based liquid solution into an aerosol mist containing different concentration of nicotine. Our preliminary study showed an increase in Raw, a concomitant decrease in sGaw and an increase in slope of phase III in a limited number of subjects immediately after smoking a single e–cig containing nicotine.
Methods:
We extended our protocol in a larger group of never smokers and in smokers. We implemented the same protocol with a nicotine free e-cig in a group of never smokers. We studied 60 subjects before and after smoking an e-cig containing 11mg nicotine (Group A). Group A: 9 never smokers and 51 smokers (24 had no overt airways disease, 11 asthma, 16 COPD). Another group of 10 never smokers used a nicotine free e-cig (Group B). Lung function assessed pre and post e-cig use including lung volumes, airway resistance (Raw), specific airway conductance (sGaw) and the slope of phase III. The same brand of e-cig used in both groups, with 11 and 0mg of nicotine.
Results:
Group A: a significant increase in Raw was shown in smokers and in never smokers (0.284±0.13-0.308±0.14; p= 0.033, 0.246±0.07-0.292±0.05; p=0.006) with significant decrease in sGaw (1.197±0.50-1.060±0.42; p= 0.009, 1.313±0.22-1.109±0.18; p= 0.043). Increased slope in phase III was shown only in asthmatic patients (p=0.008). Group B: increase in Raw (0.247±0.03-0.333±0.08; p=0.005) and a decrease in sGaw (1.213±0.29-0.944±0.18; p=0.009) noted.
Conclusions:
The present study supports our preliminary results showing increased Raw and a concomitant decrease in sGaw. These changes might be due to the vaporizing liquid but not to the inhaled nicotine per se.
RELATED ARTICLE
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.